Bioventus Inc.
BVS
$8.16
-$0.99-10.82%
| 12/31/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 97.44% | 33.94% | -551.78% | 96.72% | 80.91% |
| Total Depreciation and Amortization | 0.35% | -11.22% | -10.34% | -28.46% | -113.12% |
| Total Amortization of Deferred Charges | -16.67% | -- | -- | -- | 50.46% |
| Total Other Non-Cash Items | 31.47% | 141.85% | 759.63% | -98.69% | -22.53% |
| Change in Net Operating Assets | -206.73% | 97.18% | 85.57% | -282.86% | -74.69% |
| Cash from Operations | 86.25% | 224.06% | 40.45% | -341.16% | 97.83% |
| Capital Expenditure | -55.56% | 96.86% | 94.49% | 91.83% | 89.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 11,216.22% | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 93.84% | -- |
| Cash from Investing | 4,178.51% | 96.86% | -100.23% | 93.36% | 82.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 86.29% | 84.72% | 100.00% |
| Issuance of Common Stock | 598.10% | 39.29% | 338.13% | 110.71% | -85.41% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2,603.49% | -13.69% | 91.05% | 20.01% | -1,463.64% |
| Cash from Financing | -306,007.14% | -95.60% | 87.40% | -115.49% | 99.74% |
| Foreign Exchange rate Adjustments | -660.60% | 205.91% | -274.58% | -218.00% | -65.02% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -114.72% | 532.47% | 138.51% | -177.24% | 498.31% |
